{"id":{"repo_id":"rowan","oai_identifier":"oai:rdw.rowan.edu:etd-4260"},"canonical_url":"https://search.ndltd.org/etd/rowan/oai:rdw.rowan.edu:etd-4260","repository":{"repo_id":"rowan","name":"Rowan University","base_url":"https://rdw.rowan.edu/do/oai/"},"display":{"title":"POTENT AND SELECTIVE SMALL MOLECULE MCL-1 INHIBITOR DEMONSTRATES ANTI-MYELOMA ACTIVITY AND OVERCOMES CHEMOTHERAPY RESISTANCE","abstract":"Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and nearly all patients relapse. Poor patient outcomes demonstrate that myeloma cells are \"born to survive” which means they can adapt and evolve following treatment. Thus, new therapeutic approaches to combat survival mechanisms and target treatment resistance are required. Importantly, Mcl-1, anti-apoptotic protein, is required for the development of MM and treatment resistance. This study looks at the possibility of KS18, a selective Mcl-1 inhibitor, to treat MM and overcome resistance. Our investigation demonstrates that KS18 effectively induces cell death in MM by dual regulatory mechanisms targeting Mcl-1 protein at both transcriptional and post-translational levels. KS18 triggered caspase-dependent apoptosis in MM patient samples and bortezomib-resistant cells, synergizing with venetoclax to boost apoptosis. Furthermore, the study shows the tremendous impact of KS18 in inhibiting colony formation in bortezomib-resistant cells and demonstrates tumor shrinkage in KS18-treated NSG mice without notable toxicity signs, indicating its powerful anti-neoplastic and anti-resistance characteristics. This study strongly implies that KS18 may treat MM and provide new hope to patients who are experiencing recurrence or resistance.","abstract_html":"Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and nearly all patients relapse. Poor patient outcomes demonstrate that myeloma cells are &quot;born to survive” which means they can adapt and evolve following treatment. Thus, new therapeutic approaches to combat survival mechanisms and target treatment resistance are required. Importantly, Mcl-1, anti-apoptotic protein, is required for the development of MM and treatment resistance. This study looks at the possibility of KS18, a selective Mcl-1 inhibitor, to treat MM and overcome resistance. Our investigation demonstrates that KS18 effectively induces cell death in MM by dual regulatory mechanisms targeting Mcl-1 protein at both transcriptional and post-translational levels. KS18 triggered caspase-dependent apoptosis in MM patient samples and bortezomib-resistant cells, synergizing with venetoclax to boost apoptosis. Furthermore, the study shows the tremendous impact of KS18 in inhibiting colony formation in bortezomib-resistant cells and demonstrates tumor shrinkage in KS18-treated NSG mice without notable toxicity signs, indicating its powerful anti-neoplastic and anti-resistance characteristics. This study strongly implies that KS18 may treat MM and provide new hope to patients who are experiencing recurrence or resistance.","abstract_has_math":false,"creators":["Al-Odat, Omar Sami Faleh"],"institution":null,"degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Chemistry and Biochemistry","degree_department":null,"school":null,"contributors":["Manoj K. Pandey, Ph.D.","Subash Jonnalagadda, Ph.D.","Kandalam Ramanujachary, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:59:46Z","subjects":["Bcl-2; Bortezomib; Drug resistance; Mcl-1; Multiple myeloma (MM); Venetoclax","Multiple myeloma","Drug development","Chemistry","Medicinal and Pharmaceutical Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://rdw.rowan.edu/etd/3254","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://rdw.rowan.edu/etd/3254","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://rdw.rowan.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ardw.rowan.edu%3Aetd-4260","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Manoj K. Pandey, Ph.D.","Subash Jonnalagadda, Ph.D.","Kandalam Ramanujachary, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Al-Odat, Omar Sami Faleh"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2024-06-24T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2024-06-20T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Bcl-2; Bortezomib; Drug resistance; Mcl-1; Multiple myeloma (MM); Venetoclax","Multiple myeloma","Drug development","Chemistry","Medicinal and Pharmaceutical Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://rdw.rowan.edu/etd/3254"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and nearly all patients relapse. Poor patient outcomes demonstrate that myeloma cells are \"born to survive” which means they can adapt and evolve following treatment. Thus, new therapeutic approaches to combat survival mechanisms and target treatment resistance are required. Importantly, Mcl-1, anti-apoptotic protein, is required for the development of MM and treatment resistance. This study looks at the possibility of KS18, a selective Mcl-1 inhibitor, to treat MM and overcome resistance. Our investigation demonstrates that KS18 effectively induces cell death in MM by dual regulatory mechanisms targeting Mcl-1 protein at both transcriptional and post-translational levels. KS18 triggered caspase-dependent apoptosis in MM patient samples and bortezomib-resistant cells, synergizing with venetoclax to boost apoptosis. Furthermore, the study shows the tremendous impact of KS18 in inhibiting colony formation in bortezomib-resistant cells and demonstrates tumor shrinkage in KS18-treated NSG mice without notable toxicity signs, indicating its powerful anti-neoplastic and anti-resistance characteristics. This study strongly implies that KS18 may treat MM and provide new hope to patients who are experiencing recurrence or resistance."]},{"key":"dc:title","label":"Title","values":["POTENT AND SELECTIVE SMALL MOLECULE MCL-1 INHIBITOR DEMONSTRATES ANTI-MYELOMA ACTIVITY AND OVERCOMES CHEMOTHERAPY RESISTANCE"]}]}],"canonical_facts":{"dc:contributor":["Manoj K. Pandey, Ph.D.","Subash Jonnalagadda, Ph.D.","Kandalam Ramanujachary, Ph.D."],"dc:creator":["Al-Odat, Omar Sami Faleh"],"dc:date.available":["2024-06-24T07:00:00Z"],"dc:date.created":["2024-06-20T07:00:00Z"],"dc:description.abstract":["Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and nearly all patients relapse. Poor patient outcomes demonstrate that myeloma cells are \"born to survive” which means they can adapt and evolve following treatment. Thus, new therapeutic approaches to combat survival mechanisms and target treatment resistance are required. Importantly, Mcl-1, anti-apoptotic protein, is required for the development of MM and treatment resistance. This study looks at the possibility of KS18, a selective Mcl-1 inhibitor, to treat MM and overcome resistance. Our investigation demonstrates that KS18 effectively induces cell death in MM by dual regulatory mechanisms targeting Mcl-1 protein at both transcriptional and post-translational levels. KS18 triggered caspase-dependent apoptosis in MM patient samples and bortezomib-resistant cells, synergizing with venetoclax to boost apoptosis. Furthermore, the study shows the tremendous impact of KS18 in inhibiting colony formation in bortezomib-resistant cells and demonstrates tumor shrinkage in KS18-treated NSG mice without notable toxicity signs, indicating its powerful anti-neoplastic and anti-resistance characteristics. This study strongly implies that KS18 may treat MM and provide new hope to patients who are experiencing recurrence or resistance."],"dc:identifier":["https://rdw.rowan.edu/etd/3254"],"dc:subject":["Bcl-2; Bortezomib; Drug resistance; Mcl-1; Multiple myeloma (MM); Venetoclax","Multiple myeloma","Drug development","Chemistry","Medicinal and Pharmaceutical Chemistry"],"dc:title":["POTENT AND SELECTIVE SMALL MOLECULE MCL-1 INHIBITOR DEMONSTRATES ANTI-MYELOMA ACTIVITY AND OVERCOMES CHEMOTHERAPY RESISTANCE"],"thesis:degree_discipline":["Chemistry and Biochemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"]},"updated_at":"2026-11-19T08:59:46Z"}